Maravai LifeSciences Holdings, Inc. (MRVI)

Market Cap	976.42M
Revenue (ttm)	288.95M
Net Income (ttm)	-119.03M
Shares Out	132.31M
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	30.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	251,409
Open	7.54
Previous Close	7.67
Day's Range	7.31 - 7.63
52-Week Range	4.52 - 16.62
Beta	0.01
Analysts	Buy
Price Target	11.56 (+56.64%)
Earnings Date	May 8, 2024

About MRVI

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in tw...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 20, 2020
• Employees: 650
• Stock Exchange: NASDAQ
• Ticker Symbol: MRVI

Analyst Forecast

According to 10 analysts, the average rating for MRVI stock is "Buy." The 12-month stock price forecast is $11.56, which is an increase of 56.64% from the latest price.

Price Target

$11.56

(56.64% upside)

Analyst Consensus: Buy